

7 Literatur

- 1) Schwabe, U., Antidementiva, in Arzneiverordnungsreport 2005, U. Schwabe and D. Paffrath, Editors. 2005, Springer: Berlin: 350-368.
- 2) Wallesch C-W, Förstl H (Hrsg). Demenzen. Stuttgart: Thieme 2005
- 3) Sachdev P. Is it time to retire the term “dementia”? J Neuropsychiatry Clin Neurosci. 2000;12: 276-279.
- 4) Wettstein A. Alzheimer und vaskuläre Demenz unterscheiden? Heute nicht mehr zeitgemäß, Fortschritte der Medizin. NrIII-IV/2001:139-140.
- 5) Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. The Nun Study; brain infarction and the clinical expression of Alzheimer Disease. J Am Med Assoc 277(1997): 813-817.
- 6) Fu C, Chute DJ, Farag ES, Garakin J, Cummings JL, Vinters HV. Comorbidity in dementia. An autopsy study. Arch Pathol Lab Med 2004;128: 32-38.
- 7) Schaie, K. The Seattle Longitudinal Study: a thirty-five-year inquiry of adult intellectual development. Z Gerontol, 1993. 26(3):129-37.
- 8) Breteler MM, Ott A, Hofman A. Incidence and risk of dementia. The Rotterdam Study. Am J Epidemiol. 1998;147: 574-580.
- 9) Bickel H. Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual incidence in Germany. Gesundheitswesen 2000;62: 211-218.
- 10) Bickel H: Dementia in advanced age: estimating incidence and health care costs. Z Gerontol Geriatr 2001; 34: 108–115.
- 11) Hallauer JF, Schons M, Smala A. Untersuchung von Krankheitskosten bei Patienten mit Alzheimer-Erkrankung in Deutschland. Gesundh ökon Qual manag 2000;5:73-79.
- 12) Mahlberg R. Gutzmann H. Diagnostik von Demenzerkrankungen. Dtsch Arztebl 2005; 102: A 2032–2039.
- 13) Nagy Z, Esiri MM, Hindley NJ, Joachim C, Morris JH, King EM. Accuracy of clinical operational diagnostic criteria for Alzheimer’s disease in relation to different pathological diagnostic protocols. Dement Geriatr Cogn Disord 1998; 9: 219–226.

- 14) Wolfson C, Wolfson DB, Asgharian M, M'LAN CE, Ostbye T, Rockwood K, Hogan DB. A reevaluation of the duration of survival after the onset of dementia. *N Engl J Med* 2001; 344: 1111–1116.
- 15) Ueki A, Shinjo H, Shimode H, Nakajima T, Morita Y. Factors associated with mortality in patients with early-onset Alzheimer's disease: a five-year longitudinal study. *Int J Geriatr Psychiatry* 2001; 16: 810–815.
- 16) McGlone J, Gupta S, Humphrey D, Oppenheimer S, Mirsen T, Evans DR. Screening for early dementia using memory complaints from patients and relatives. *Arch Neurol* 1990; 47: 1189–1193.
- 17) Patterson CJ, Gauthier S, Bergman H et al.: The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. *CMAJ* 1999; 160: 1–15.
- 18) Folstein MF, Folstein SE, McHugh PR. „Mini-mental state“. A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12: 189–198.
- 19) Sunderland T, Hill JL, Mellow AM, Lawlor BA, Gundersheimer J, Newhouse PA, Grafman JH. Clock drawing in Alzheimer's disease. A novel measure of dementia severity. *J Am Geriatr Soc* 1989; 37: 725–729.
- 20) Kessler J, Calabrese P, Kalbe E, Berger F: DemTect: A new screening method to support diagnosis of dementia. *Psycho* 2000; 26: 343–347.
- 21) Ihl R, Grass-Kapanke B, Lahrem P, Brinkmeyer J, Fischer S, Gaab N, Kaupmannsennecke C. Entwicklung und Validierung eines Tests zur Früherkennung der Demenz mit Depressionsabgrenzung. *Fortschritte der Neurologie und Psychiatrie* 2000; 68: 413–422.
- 22) Zaudig M, Mittelhammer J, Hiller W, Pauls A, Thora C, Morinigo A, Mombour W. SIDAM– A structured interview for the diagnosis of dementia of the Alzheimer type, multi-infarct dementia and dementias of other aetiology according to ICD-10 and DSM-III-R. *Psychol Med* 1991; 21: 225–236.
- 23) Morris JC, Heyman A, Mohs RC et al.: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. *Neurology* 1989; 39: 159–1165.

- 24) Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2001; 56: 1143–1153.
- 25) Bonte FJ, Weiner MF, Bigio EH, White CL: III. SPECT imaging in dementias. *J Nucl Med* 2001; 42: 1131– 1133.
- 26) Silverman DH, Small GW, Chang CY et al.: Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. *JAMA* 2001; 286:2120–2127.
- 27) Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST: Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2001; 56: 1133–1142.
- 28) Seshadri S. Apolipoprotein E4 allele and the lifetime risk of Alzheimer's disease. *Arch Neurol* 1995;52:1074-1079.
- 29) Gutzmann H, Zank S. Demenzen. Medizinische und psychosoziale Interventionsmöglichkeiten. *Grundriss der Gerontologie, Band 17, Stuttgart (2004): Kohlhammer.*
- 30) Förstl H, Maelicke A, Weichel C. Demenz. Taschenatlas spezial. 2005.
- 31) Del-Ser T, Munoz DG, Hachinski V . Temporal pattern of cognitive decline and incontinence is different in Alzheimer's disease and diffuse Lewy body disease. *Neurology*.1996;46: 682-686.
- 32) McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. *Lancet*, 2000. 356(9247): 2031-6.
- 33) McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. *Bmj* 1992;305(6855):673-8.
- 34) Birks J, Grimley Evans J, Van Dongen M. Ginkgo biloba for dementia and cognitive impairment (Cochrane Review). In: *The Cochrane Library, Issue 3, 2003. Oxford.*

- 35) Arzneimittelkommission der deutschen Ärzteschaft, Blutungen unter der Gabe von Ginkgo-biloba-Extrakten. Cave Kombination mit Gerinnungshemmern, Deutsches Ärzteblatt 2002, Jahrgang 99, Heft 33: A2214.
- 36) Pratt RD, Perdomo CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. *Ann N Y Acad Sci* 2002;907:513-522.
- 37) Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamin in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease. *Lancet* 2002;359:1283-1290.
- 38) Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine. *Int J Geriatr Psychiatry* 1999. 14(2): 135-46.
- 39) Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). *Stroke* 2002;33(7):1834-9.
- 40) Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, Mohs RC, Thal LJ, Whitehouse PJ, DeKosky ST, Cummings JL. Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*, 2001. 56 (9): 1154-66.
- 41) Grasel E, Wiltfang J, Kornhuber J. Non-drug therapies for dementia: an overview of current situation with regard to proof of effectiveness. *Dement Geriatr Cogn Disord*. 2003;15:115-125.
- 42) Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. *Neurology* 1998. 50(1): 136- 45.
- 43) Rogers, S. L. and Friedhoff, L. T., The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo- Controlled Trial. The Donepezil Study Group. *Dementia*, 1996. 7(6): 293-303.
- 44) Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG. Donepezil zur symptomatischen Behandlung leichter bis mittelschwerer Alzheimer- Krankheit. *Int*

- J Geriatr Psychiatry 2004;19:624-633 (dt. Übersetzung ABW Wissenschaftsverlag Berlin).
- 45) Birks JS, Melzer D, Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford.
 - 46) Rosen WG, Mohs RC, Davis KL. A new Rating scale for Alzheimer's disease. American J Psychiatr, 1984;141:1356-64.
 - 47) McRea T, Knopman D, Duttagupta S, Ieni J, Provenzano G. Donepezil delays time to nursing home placement in patients with Alzheimer's disease. Presented at: Annula Scientific Meeting of American Geriatrics Society. J Am Geriatr Soc. 2001;49: 132.
 - 48) Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stählein HB, Hartman R, Gharabawi M, Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial; BMJ, 1999. 318: 633-640.
 - 49) Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon(TM) (ENA-713) in Alzheimer's disease: An overview. Journal of Drug Development & Clinical Practice, 1996. 8(2): 109-116.
 - 50) Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease; Int. J. Geriatr. Psychopharmacol; 1998. 1: 55-65.
 - 51) Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Related Articles, Links. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2000;(4).
 - 52) Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford.
 - 53) Fachinformation: Galantamin; Fachinfo-Service, Sep/2005. www.fachinfo.de.
 - 54) Reisberg B, Stoffler A, Ferris SH. Memantine in moderately severe to severe Alzheimer's disease: results of a placebo-controlled 6 month trial. Neurobiol. Aging 2000;21: 275.

- 55) Areosa Sastre A, Sherriff F. Memantine for dementia (Cochrane Review). In: The Cochrane Library. Oxford: Update Software; 2005.
- 56) Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. *Jama*, 2004. 291(3): 317-24.
- 57) Kanowski S, Herrmann WM, Stephan K, Wierich W, Horr R. Proof of efficacy of the ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. *Pharmacopsychiatry*.1996. 29(2): 47-56.
- 58) LeBars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. *JAMA* 1997. 278: 1327-32.
- 59) López-Arrieta, Birks J. Nimodipine for primary degenerative, mixed and vascular dementia (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
- 60) Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T. The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. *J Neurol Sci*, 2000.175(2): 116-23.
- 61) Flicker L, Grimley Evans J. Piracetam for dementia or cognitive impairment (Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
- 62) Grossberg GT. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. *Int Psychogeriatr* 14 Suppl 1:27-49.
- 63) Nyth AL, Gottfries CG. The clinical efficacy of citalopram in the treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. *Br J Psychiatr*.1990;157: 894-901.
- 64) Raji MA, Brady SR. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. *Ann Pharmacother*. 2001 Sep;35(9):1024-7.
- 65) Bhana, Spencer CM. Risperidon: a review of its use in the management of the BPSD. *Drugs aging*.2000;16:451-71.

- 66) ÄZQ, Leitlinien-Clearingbericht "Demenz". ÄZQ Schriftenreihe Band 20, 2005, Berlin: Ärztliches Zentrum für Qualität in der Medizin (Gemeinsame Einrichtung von BÄK und KBV). 201.
- 67) Lawton M, Brody E. Assessment of older people: self-maintaining and instrumental activities of daily living. *The Gerontologist*, 1969;9:179-186.
- 68) Schneider LS. Clinical global impressions in Alzheimer's clinical trials. *International Psychogeriatrics*. 1996;8:277-288.
- 69) www.kompetenznetz-demenzen.de; September 2004.
- 70) Fröhlich L, Schmitt B, Calabrese P et al. Neue Optionen in der Pharmakotherapie der Alzheimer-Krankheit nach Zulassung von Memantine? *Dtsch Med Wochenschr* 2005;130:408-412.
- 71) Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P; AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. *Lancet*, 2004. 363(9427):2105-15.
- 72) NICE: Appraisal Consultation Document: Alzheimer's disease - donepezil, rivastigmine, galantamine and memantine (review). 2005, National Institute of Clinical Excellence (NICE).
- 73) Winblad, B., Brodaty, H., Gauthier, S., Morris, J. C., Orgogozo, J. M., Rockwood, K., Schneider, L., Takeda, M., Tariot, P., Wilkinson, D., Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success? *Int J Geriatr Psychiatry*, 2001. 16(7): 653-66.
- 74) Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van den Bussche H. Cholinesterase inhibitors for patient with Alzheimer's disease: systemic review of randomised clinical trials. *BMJ* 2005;331:321- 327.
- 75) Stoppe G, Pirk O, Haupt M. Treatment of Alzheimer's disease utilising the best available evidence-based medicine utopia? *Gesundheitswesen*. 2005. 67(1): 20-6.
- 76) Kaduszkiewicz H, Beck-Bornholdt HP, van den Bussche H, Zimmermann T. Doubtful evidence for the use of the cholinesterase inhibitor donepezil in patients with dementia - a systematic review. *Fortschr Neurol Psychiatr*, 2004. 72(10): 557-63.

- 77) Holmes, C., et al., AD2000: design and conclusions. Lancet, 2004. 364(9441):1213-4; author reply 1216-7. Schneider, L.S., AD2000: donepezil in Alzheimer's disease. Lancet, 2004. 363(9427):2100-1.
- 78) Riepe M, Fröhlich L, Gertz H-J, Haupt M, Kohler J, Mielke R, Damerau-Dambrowski vd V, Kurz A. Evidenzbasierte medikamentöse Therapie der Alzheimer-Erkrankung. Dtsch Ärztebl 2005;102:A3587-3593.
- 79) Sachverständigenrat zur Begutachtung der Entwicklung im Gesundheitswesen, 2001.
- 80) Geldmacher M, MDK Baden-Württemberg, 2004. www.zukunftsforum-demenz.de/pdf/4338_Doku7_Innen.pdf: 25-29.
- 81) Haupt M, Rosenfeld S, Stoppe G. Die ambulante Versorgung von Patienten mit Alzheimer Demenz. MMW 2004(146):51-56.
- 82) Bohlken J. Neue Versorgungsformen für Demenz-Patienten. Neurotransmitter, 2005;1:2-3.
- 83) Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Mastey V, Haglund A, Zhang R, Miceli R, Chin W, Subbiah P. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord, 2003.15(1): 44-54.
- 84) Hallauer JF, Kurz A. Weißbuch Demenz. Versorgungssituation relevanter Demenzerkrankungen in Deutschland. Stuttgart: Thieme 2002.
- 85) Helou A. Der Beitrag von medizinischen Leitlinien zur Aufdeckung und Reduktion von Über-, Unter- und Fehlversorgung. Arzneim.-Forsch./Drug.Res. 2002;52, 4:322-23.
- 86) GEK: Ergebnisse der Auswertung von Krankenkassendaten zur Demenzbehandlung, Arzneimittelreport 2005.
- 87) H.Mann, Whitney D. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Statist;18(1947):50-60.
- 88) Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res 1975. 12: 189-98. Dt.Fassung von Kessler J, Markowitsch HJ, Denzler PE. MMST: Mini-Mental-Status-Test. Weinheim: Beltz Test (1990).

- 89) Ivemeyer D, Zerfaß R. Demenztests in der Praxis; Urban&Fischer: München, Jena 2002 S.74.
- 90) Mahoney FL, Barthel DW. Functional evaluation: the BARTHEL index. Maryland State Medical Journal, 1965, 14:61-65.
- 91) AVP: Therapieempfehlungen der Arzneimittelkommission der deutschen Ärzteschaft: Demenz, Köln: 2004(3).
- 92) Deutsche Gesellschaft für Neurologie (DGN): Diagnose und Therapie der Alzheimer-Demenz (AD) und der Demenz mit Lewy-Körperchen (DLB), Leitlinien für Diagnostik und Therapie in der Neurologie. 2003
Neurodegenerative Demenzen. Leitlinien für Diagnostik und Therapie; 3. überarbeitete Auflage 2005; Georg Thieme Verlag Stuttgart
- 93) Deutsche Gesellschaft für Psychiatrie und Psychotherapie (DGPPN): Behandlungsleitlinie Demenz. Praxisleitlinien in Psychiatrie und Psychotherapie, Ed. W. Gaebel and P. Falkai. 2004, Darmstadt: Steinkopff Verlag.
- 94) Medizinisches Wissensnetzwerk evidence.de der Universität Witten/Herdecke. Leitlinie Diagnose, Therapie und Versorgung bei Demenz Version 3/2001, 12/2001 und 10/2003.
- 95) AGS at: www.americangeriatrics.org/products/positionpapers/index.shtml#1; Sep/2005.
- 96) Stat. Bundesamt, Diagnosedaten der Krankenhaus-Patienten, Fachserie 12, Reihe 6.2.1, 2005.
- 97) 4.Altenbericht der Bundesregierung. [www.bmfsfj.de/ Kategorien/ Forschungsnetz /forschungsberichte,did=18370](http://www.bmfsfj.de/Kategorien/Forschungsnetz/forschungsberichte,did=18370). 11/2005.
- 98) Wagner M, Schütze Y, Lang FR in Mayer KU, Baltes PB(Hrsg)Die Berliner Alters studie:Soziale Beziehungen alter Menschen. Berlin 1999, Akademie Verlag:306.
- 99) Boyd C. Clinical Practice Guidelines, JAMA 2005,294: 714-724.
- 100) Sandholzer H, Breull A , Fischer GC: Früherkennung und Frühbehandlung von kognitiven Funktionseinbußen: eine Studie über eine geriatrische Vorsorgeuntersuchung im unausgelesenen Patientengut der Allgemeinpraxis. Z Gerontol Geriat 1999, 32,172-178.
- 101) Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. J Am Med Assoc. 1990;263:1097-1101.

- 102) Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP. Delirium in Alzheimer disease. *Alzheimer Dis Assoc Disord.* 1997;11:16-20.
- 103) Bauer J. Die Alzheimer-Krankheit. Stuttgart;Schattauer, 1994:15.
- 104) Hach I, Rentsch A, Krappweis J, Kirch W. Psychopharmakaverordnungen an älteren Menschen. Ein Vergleich zwischen Patienten aus Alten- und Pflegeheimen, ambulant behandelten Pflegefällen und ambulanten Patienten ohne Pflegebedarf. *Zeitschrift für Gerontologie und Geriatrie*; 37, (3) 2004: 214 – 220.
- 105) Beers MH. Inappropriate medication use in community-residing older persons. *Arch Intern Med.* 1994 Oct 10;154(19):2195-200.
- 106) Förstl H (Hrsg.). Demenzen. Perspektiven in Praxis und Forschung. München Urban&Fischer 2005.
- 107) Rosen WG et al. Pathological verification of ischemic score in differentiation of dementias. *Ann Neurol*;7, 1980: 486-488.
- 108) Stein R. Schwieriger Spagat zwischen Wissenschaft und Praxis. *Berliner Ärzteblatt.* 2006;28-29.
- 109) Steinhagen-Thiessen E, Borchelt M. Die Berliner Altersstudie: Morbidität, Medikation und Funktionalität im Alter. Berlin 1999, Akademie Verlag: 151-183.
- 110) Steinhagen-Thiessen E, Hanke B (Hrsg). Neurogeriatrie – auf einen Blick. Blackwell Verlag : Berlin-Wien 2003.
- 111) Loeb C, Gandolfo C. Diagnostic evaluation of degenerative and vascular dementia. *Stroke.* 1983; 14: 399-401.
- 112) Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. *BMJ.* 2005 Nov 19;331(7526):1169. Epub 2005 Nov 11. Review.
- 113) Finck U. Genetische Faktoren bei Alzheimer-Demenz. *Dtsch Ärztebl* 2006; 103(15):A 1010-6.
- 114) Kliegel M, Moor C, Rott C. Cognitive status and development in the oldest: a longitudinal analysis from Heidelberg Centenarian Study. *Arch Gerontol Geriatr.* 2004; 39(2):143-56.
- 115) Mary S. Mittelman, Steven H. Ferris, Emma Shulman, Gertrude Steinberg & Bruce Levin (1996). A family intervention to delay nursing home placement of patients

- with alzheimer's disease: A randomized controlled trial. *Journal of the american medical association*, 276, 1725-1731.
- 116) Jeffrey L. Cummings, „Behavioral Disturbances in Alzheimer's Disease: Relevance, Assessment and Treatment“, Live Online Seminar, EFNS Congress, Athen, 19. September 2005.
- 117) Pitkala KH, Laurila JV, Strandberg TE, Tilvis RS. Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards. *Int Psychogeriatr*. 2004 Mar;16 (1):61-74.
- 118) van den Bussche H, Kaduszkiewicz H: Verschreibungsmuster und Wirksamkeitsvermutung von Antidementiva. *Nervenheilkunde* 2005; 24: 485-92.
- 119) Petersen, R.C., Smith, G.E., Waring, S.C., Ivnik, R.J., Tangalos, E.G. & Kokmen, E. (1999). Mild Cognitive Impairment: Clinical characterization and outcome. *Archives of Neurology*, 56, 303-308.
- 120) Reischies FM, Bürker BS. Leichte Kognitive Störung und Mild Cognitive Impairment. *Klinisch-neuropsychologische Diagnostik der frühen Alzheimer Demenz Zeitschrift für Gerontopsychologie & -psychiatrie* 2005 Vol. 18, No. 4, 203-225.
- 121) Oleske DM et al.: Epidemiology of injury in people with Alzheimer's disease. *JAGS* 43 (1995), 741-746.
- 122) Projekt Fraktur und Demenz (FRANZ). Rehabilitation von Patienten mit Schenkelhalsfraktur und Demenz; Projektmitarbeiter: Dr. G. Lämmler, Dr. M. Borchelt, S. Mix, Prof. Dr. E. Steinhagen-Thiessen (Ltg.)
- 123) Buchner DM, Larson EB. Falls and fractures in patients with Alzheimer-type dementia -, - *JAMA*, 1987 - jama.highwire.org